Maze Therapeutics
MAZE
165 hedge funds and large institutions have $1.54B invested in Maze Therapeutics in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 25 closing their positions.
136% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $4.38M
96% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 25
61% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 36
15% more funds holding
Funds holding: 143 → 165 (+22)
3.45% more ownership
Funds ownership: 100.51% → 103.96% (+3.4%)
23% less capital invested
Capital invested by funds: $2B → $1.54B (-$460M)
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$121M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$52M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$33.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$36.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$33.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$23.7M |
| 4 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$19.9M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$17M |
MAZE Hedge Fund Activity: Q1 2026 in Review
165 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q1 2026, worth a combined $1.54B — down 23% from $2B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new MAZE positions and 25 closed out — a net gain of 24 holders — while 58 added to existing stakes and 36 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $121M. The largest seller was Bellevue Group, exiting entirely with an estimated $36.8M sold.
- 165 institutional investors held Maze Therapeutics (MAZE) as of Q1 2026, up from 143 in Q4 2025.
- Funds reported $1.54B of Maze Therapeutics stock for Q1 2026, down 23% quarter-over-quarter.
- 49 funds opened new Maze Therapeutics positions in Q1 2026 and 25 closed out, a net change of +24 holders.
- The largest Maze Therapeutics buyer in Q1 2026 was Paradigm Biocapital Advisors, an estimated $121M added.
- The largest Maze Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $36.8M sold.
Based on aggregated 13F filings for Q1 2026.